SEC Form 4 · accession 0001179110-16-027914

MADRIGAL PHARMACEUTICALS, INC. · MDGL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Medical Officer, EVP R&D · Director · 10% Owner

Period of report

Jul 22, 2016

Accepted (ET)

Jul 26, 2016 · 5:25 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001157601

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jul 22, 2016	A	729,066	$0.00	A	729,066	I	SQN, LLC
Common Stock^F1	Jul 22, 2016	A	404,132	$0.00	A	404,132	D
Common Stock	Jul 22, 2016	A	28,740	$0.00	A	432,872	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)	$9.45	Jul 22, 2016	A	143,557	A	Jul 22, 2016	Jul 22, 2026	Common Stock	143,557	143,557	D

F1Shares issued relate to the exchange of shares of Madrigal Pharmaceuticals, Inc. ("Madrigal"), as a private company, for shares of Synta Pharmaceuticals Corp. ("Synta"), per Synta's agreement to acquire Madrigal, dated April 13, 2016 (the "Merger"). After the completion of the Merger, Synta changed its name to Madrigal Pharmaceuticals, Inc.
F2Dr. Taub disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Exhibit List: Exhibit 24.1 Power of Attorney